FDA Approved: OLUMIANT — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

FDA approves Eli Lilly's supplemental application for OLUMIANT (baricitinib). This action updates the labeling to reflect expanded indications for baricitinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Atopic Dermatitis
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• Olumiant (baricitinib)

Snippet

SUPPL AP for OLUMIANT (BARICITINIB)